Infectious Disease Treatments: Antibiotic Resistance and New Therapeutics
Antibiotic resistance deaths reached 1.27M globally in 2024 creating urgent demand for new therapeutics. Antibiotic development received increased funding with 42 candidates in development by 2024, double the 2020 count. Novel approaches like phage therapy, antimicrobial peptides, and microbiome therapeutics advanced toward commercialization addressing resistance challenges.
Drivers, Challenges & Trends
Key Market Drivers
Market growth expected at strong CAGR through the forecast period, driven by rising demand, technology adoption, and expanding end-user applications globally.
Growth Challenges
Complex regulatory landscapes, high R&D costs, supply chain constraints, and competitive intensity present challenges for market participants.
Emerging Trends
Digital transformation, AI integration, sustainability initiatives, and evolving consumer preferences are reshaping industry dynamics and creating new opportunities.
Strategic Opportunities
Regional expansion, product innovation, strategic partnerships, and technology-enabled solutions offer significant growth potential for forward-looking companies.
What's Inside the Report
- Executive Summary
- Infectious Disease Market
- Resistance Landscape
- Antibiotic Pipeline
- Novel Therapies
- Phage Therapy
- Regulatory Pathways
- Market Incentives
- Appendix
Sample Report Content
Get a glimpse of the comprehensive analysis included in this report.
Market Overview
Antibiotic resistance deaths reached 1.27M globally in 2024 creating urgent demand for new therapeutics. Antibiotic development received increased funding with 42 candidates in development by 2024, double the 2020 count. Novel approaches like phage therapy, antimicrobial peptides, and microbiome therapeutics advanced toward commercialization addressing resistance challenges.
Market Segmentation Breakdown
By Type
By Application
By Distribution Channel
By Region
Our Research Approach
Infectious disease program tracking, 180 infectious disease specialist interviews, resistance pattern analysis, therapeutic assessment
Data Sources
Companies Profiled
Strategic profiles of key players with SWOT analysis, financials, product portfolios, and recent developments included in this report.